Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: A phase II study

Clinical Cancer Research

Volumn 2, Issue 10, 1996, Pages 1693-1697

  Chambers, Setsuko K ^a   Davis, Carol A ^a   Schwartz, Peter E ^a   Kohorn, Ernest I ^a   Chambers, Joseph T ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CYCLOSPORIN A;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; MIDDLE AGED; NAUSEA; NEUTROPENIA; OVARIAN NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0029958714     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Neijt, J. P., ten Bokkel Huinink, W. W., van der Burg, M. E. L., van Oosterom, A. T , Willemse, P. H. B., Vermorken, J. B., van Linden, A. C. M., Heintz, A. P. M., Aartsen, E., van Lent, M., Trimbos, J. B., and de Meijer, A. J. Long-term survival in ovarian cancer. Eur. J. Cancer, 27: 1367-1372, 1991.
2. Sutton, G. P., Stehman, F. B., Einhorn, L. H., Roth, L. M., Blessing, J. A., and Ehrlich, C. E. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J. Clin. Oncol., 7: 223-229, 1989.
3. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl J. Med., 334: 1-6, 1996.
4. McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F., Ettinger, D., Armstrong, D., and Donehower, R. C. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111: 273-279, 1989.
5. Thigpen, J. T., Vance, R. B., and Khansur, T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer (Phila.), 71 (Suppl.): 1559-1564, 1993.
6. Markman, M., Hakes, T., Reichman, B., Lewis, J. L., Jr., Rubin, S., Jones, W., Almadrones, L., Pizzuto, F., and Hoskins, W. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol., 10. 243-248, 1992.
7. Weiss, G., Green, S., Alberts, D. S., Thigpen, J. T., Hines, H. E., Hanson, K., Pierce, I., Baker, L. H., and Goodwin, J. W. Second-line treatment of advanced measurable ovarian cancer with iproplatin: a south-west oncology group study. Eur. J. Cancer, 27. 135-138, 1991.
8. Lum, B. L., Kaubisch, S., Yahanda, A. M., Jew, L., Ehsan, M E., Brophy, N. A., Halsey, J., Gosland, M. P., and Sikic, B I. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance J. Clin. Oncol., 10: 1635-1642, 1992.
9. Erlichman, C., Moore, M., Thiessen, J. J., Kerr, I. G., Walker, S., Goodman, P., Bjarnason, G., DeAngelis, C., and Bunting, P. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res., 53: 4837-4842, 1993.
10. Sonneveld, P., Durie, B. G. M., Lokhorst, H. M., Marie, J-P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B., and Nooter, K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet, 340: 255-259, 1992.
11. Kashani-Sabet, M., Wang, W., and Scanlon, K. J. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J. Biol. Chem., 265: 11285-11288, 1990.
12. Mutch, D. G., Herzog, T. J., Chen, C. A., and Collins, J. L. The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or Adriamycin. Gynecol. Oncol., 47: 28-33, 1992.
13. Stratton, J. A , and DiSaia, P. J. Reversal of cisplatinum resistance by cyclosporin A in xenografts of fresh human ovarian carcinoma (Abstract). Proc. Am. Assoc. Cancer Res., 29: 479, 1988.
14. Manetta, A., Boyle, J., Berman, M. L , DiSaia, P. J., Lentz, S., Liao, S. Y., Mutch, D., and Slater, L. Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer (Phila.), 73: 196-199, 1994.
15. Chambers, S. K., Davis, C. A., Chambers, J. T., Schwartz, P. E., Lorber. M. I., and Handschumacher, R. E. Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Clin. Cancer Res., 2: 1699-1704, 1996.
16. Markman, M., and Hoskins, W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population (Editorial) J. Clin. Oncol., 10: 513-514, 1992
17. Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., and Lewis, J. L., Jr. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol., 9; 389-393, 1991.
18. Chambers, J. T., Chambers, S. K., Voynick, I. M., and Schwartz, P. E. Neoadjuvant chemotherapy for stage X ovarian cancer. Gynecol. Oncol., 37: 327-331, 1990.
19. Schwartz, P. E., Chambers, J. T., and Makuch, R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol. Oncol., 53: 33-37, 1994.
20. Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., and Wiltshaw, E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol., 7: 1748-1756, 1989.
21. Chambers, J. T., Chambers, S. K., and Schwartz, P. E. Correlation between measured creatinine clearance and calculated creatinine in ovarian cancer patients. Gynecol. Oncol., 36: 66-68, 1990.
22. Oken, M. M., Creech, R H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., and Carbone, P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol., 5: 649-655, 1982.
23. Rustin, G. J., van der Burg, M. E., and Berek, J. S. Advanced ovarian cancer. Tumour markers. Ann. Oncol., 4 (Suppl.): 71-77, 1993.
24. Ozols, R. F., Thigpen, J. T., Dauplat, J., Colombo, N., Piccart, M. J., Bertelsen, K., Levin, L., and Lund, B. Dose intensity. Ann. Oncol., 4 (Suppl.): 49-56, 1993.
25. Jodrell, D. I., Egorin, M. J., Canetta, R. M., Langenberg, P., Goldbloom, E. P., Burroughs, J. N., Goodlow, J. L., Tan, S., and Wiltshaw, E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol., 10: 520-528, 1992.
26. Morgan, R., Doroshow, J. H., Egorin, M., Kearns, C., Zuhowski, E., Carroll, M., Rincon, A., Coluzzi, P., Hamasaki, V., Tetef, M., Raschko, J., Leong, L., Margolin, K., Somlo, G., Shibata, S., Ahn, C., Akman, S., Yen, Y., and Chow, W. Unexpectedly severe myelosuppression of carboplatin (CBDCA)/Taxol (T)/cyclosporine (CsA) combination chemotherapy unrelated to sequence (seq) of drug administration or pharmacokinetic (PK) alterations (Abstract). Proc. Am. Soc. Clin. Oncol., 14: 464, 1995.
27. Yang, J. M., Sommer, S., and Hait, W. N. Reversal of Taxol resistance in vitro and in vivo, by trans-flupenthixol and cyclosporin A (Abstract) Proc. Am. Assoc. Cancer Res., 35: 355, 1994.
28. Horwitz, S. B., Lothstein, L., Manfredi, J. J., Mellado, W., Parness, J., Roy, S. N., Schiff, P. B , Sorbara, L., and Zeheb, R. Taxol: mechanisms of action and resistance. Ann. N.Y. Acad. Sci., 466: 733-744, 1986.
29. Twentyman, P. R., and Bleehen, N. M. Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A. Eur. J. Cancer, 27: 1639-1642, 1991.
30. Slater, L., Sweet, P., Osann, K., and Stupecky, M. Comparison of cyclosporin A and PSC-833 enhancement of VP-16 in drug sensitive tumors (Abstract). Proc. Am. Assoc. Cancer Res., 36: 342, 1995.
31. Slater, L. M., ,Cho J., and Wetzel, M. Cyclosporin A potentiation of VP-16: production of long-term survival in murine acute lymphatic leukemia. Cancer Chemother. Pharmacol., 31: 53-56, 1992.